Introduction
The increasing prevalence and burden of diabetes mellitus (DM) and heart failure (HF) have made both conditions significant public health problems in the United States and worldwide.
1,2 DM is a DM is more common and associated with poorer outcomes in Asian (Singaporean) HF patients compared to European (Swedish) HF patients. 9 Examining specific ethnicities, the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry revealed significant ethnic variation in the prevalence of DM amongst the different ethnic groups with HF across multiple nations in Asia. 10 These initial results from the ASIAN-HF registry motivate further exploration of the role of ethnicity in outcomes of patients with DM and HF around the world.
The merger of two datasets of patients with HF with reduced ejection fraction (HFrEF) from different regions of the world provides a unique opportunity to explore the burden of concomitant HF and DM and examine the association between ethnicity and outcomes.
Methods

Data sources
For this analysis, data from two cohorts of HF patients-HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training) and ASIAN-HF-were merged. The design and methodology of both studies are published 10 -13 and the combined dataset has been previously used for analyses. 14 patients from 82 centres in the United States, Canada, and France, were randomized to exercise training plus usual care or usual care alone. Median follow-up was 30 months. 13 The ASIAN-HF registry is a prospective observational registry of patients above 18 years of age, with symptomatic HF and left ventricular systolic dysfunction (LVEF ≤40%). The registry includes 5276 patients from 46 medical centres across 11 Asian regions (China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand). 11 The data variables common to both HF-ACTION and ASIAN-HF, including variables on socio-demographic information, physical examination, co-morbidities, HF medication use (i.e. angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, diuretics), Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and clinical outcomes were combined (see online supplementary Table S1 ).
Study population
The study population includes adult patients in the combined dataset with HFrEF (LVEF ≤35%). Patients were stratified by presence or absence of concomitant DM at baseline. DM was defined as the presence of clinical diagnosis (fasting plasma glucose ≥7 mmol/L or random plasma glucose ≥11.1 mmol/L or glycated haemoglobin ≥6.5%) and/or receiving anti-diabetic therapy. In both cohorts, DM status was collected at study entry as an existing diagnosis of DM by self-report and confirmed by a clinician. Ethnicity was defined by self-report and included white, black, Chinese, Malay, Indian, Japanese/Korean. or Malaysia). The minority groups in HF-ACTION (American Indian, Asian, Pacific Islander, Hispanics, Multiracial and Unknown, n = 142) and in ASIAN-HF (Thai, Filipino, Indigenous groups, and Others, n = 327) were excluded for this analysis due to small numbers. Due to small numbers, geographic proximity and clinical similarities, Japanese and Korean patients were grouped together, as in prior analyses.
10,14
Outcomes
For both HF-ACTION and ASIAN-HF, systematic follow-up was mandated by protocol and outcomes were adjudicated by an event committee using pre-specified criteria. 11, 13 In HF-ACTION, adjudicators were blinded to treatment assignment. The primary outcome was all-cause mortality at 1 year and secondary outcomes included 1-year all-cause mortality and/or first HF hospitalization, 1-year cardiovascular (CV) mortality and 1-year CV mortality and/or first HF hospitalization.
Statistical analysis
Baseline characteristics for the study population by DM status and ethnicity were described using frequencies with percentages for categorical variables and means with standard deviations or medians with interquartile range for continuous variables. We tested for differences between groups using the chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables.
Logistic regression was used to assess the association between baseline characteristics and DM. Univariable and age-adjusted analyses were first performed on the baseline characteristics. Covariates with univariable P-values <0.10 and a priori selected variables based on clinical significance were then included in the multivariable analyses in the model. Clinical correlates of DM examined included ethnicity, age, sex, body mass index (BMI), heart rate, LVEF, aetiology of HF, history of coronary artery disease (CAD), hypertension, atrial fibrillation (AF), peripheral vascular disease (PVD) and chronic kidney disease (CKD). Age was adjusted as a linear continuous term. To determine ethnic differences in the associations with DM, we also tested for interaction between ethnicity and all the baseline characteristics (including geographic region/country), and reported stratified results by ethnicity in the presence of significant interaction.
Finally, Cox proportional regression was used to assess the association of DM with the primary and secondary outcomes up to 1 year. We calculated the crude hazard ratio (HR), and adjusted by age, then further adjusted for other clinically important baseline characteristics including gender and ethnicity, vital signs at baseline, co-morbidities, medication use, and geographic region/country, as used in prior analyses. 14,15 For significant associations, we assessed for interaction by ethnicity. Geographic region/country was adjusted for when ethnicity-specific analysis was performed in the whites (USA, Canada, Europe) and in the Chinese, Malays and Indians (e.g. Singapore, Malaysia, Indonesia, India where applicable). In addition, time-to-event analyses using the competing risk approach based on the Fine and Gray model were performed for the secondary outcomes, factoring non-CV deaths as a competing risk. We used 2-tailed = 0.05 to establish statistical significance and reported 95% confidence intervals (CIs). To account for multiple comparisons, we used the Benjamini-Hochberg procedure and a false discovery rate of 0.05 to verify that the same variables were significant. All statistical analyses were performed with STATA/SE v14.0 (Stata Corp., College Station, TX, USA). index, heart rate, left ventricular ejection fraction, aetiology of heart failure, history of coronary artery disease, hypertension, atrial fibrillation, peripheral vascular disease, chronic obstructive pulmonary disease and chronic kidney disease.
Results
Prevalence of diabetes mellitus
A total of 6214 (1324 whites, 674 blacks, 1297 Chinese, 1510 Indians, 717 Malays, and 692 Japanese/Koreans) HF patients were included in this study. The overall prevalence of DM was 39.5% (n = 2454). The prevalence of DM was lowest in whites (29.3%), followed by Japanese/Koreans (34.1%), blacks (35.9%), Chinese (42.3%), Indians (44.2%), and highest in Malays (51.9%). Compared to whites, all ethnicities had significantly higher odds of DM [odds ratio (OR) 1.5-4.1, P < 0.001 for all; Figure 1 ).
Baseline characteristics and clinical correlates by ethnicity
Across all ethnicities, those with DM were older than those without DM ( Table 1) . For the white, Indian and Japanese/Korean groups, there were lower percentages of females with DM compared to without DM, but in the Chinese and Malay populations, there was a higher percentage of females with DM. Blacks had a similar percentage of females with and without DM. Across ethnicities, patients with DM had higher average BMI compared to patients without DM. Similarly, across all ethnicities, those with DM had higher rates of ischaemic aetiology of HF, CAD, prior cerebrovascular accident, PVD, and CKD and higher use of statins.
When the quality of life was tested using the KCCQ questionnaire (where higher scores reflect better health status), DM affected different domains of health status to different extent in the various ethnic groups ( HF medications for patients with DM, there was a higher use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and beta-blockers in black, white, and Japanese/Korean patients compared to Chinese, Malay, and Indian patients. However, among patients with DM, black and white patients had the lowest rates of mineralocorticoid receptor antagonist use compared to other ethnicities.
In terms of diabetic medication use, overall, among patients with DM, 71.8% were on anti-diabetic medications. Whites and blacks had the highest percentage of anti-diabetic medication use (87.9% and 87.6%, respectively), whereas Japanese/Korean ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PVD, peripheral vascular disease.
patients had the lowest percentage (60.2%). There was no significant difference among groups for use of oral diabetic medications; the difference between groups was driven by a difference in insulin use, with blacks having the highest rate of insulin (50.4%) and Japanese/Koreans having the lowest rate (11.5%).
The correlation between age, sex, BMI, CAD, hypertension, AF, PVD and CKD with DM differed significantly by ethnicity (Figure 2 , and online supplementary Table S3 ). In multivariable analysis stratified by ethnicity, increasing age was associated with higher odds of DM in all ethnic groups except whites and Japanese/Koreans (P = 0.001). Women were associated with higher adjusted odds of DM only in Malays (P = 0.015). BMI and hypertension were associated with increased odds of DM across all ethnic groups but these odds varied significantly (P < 0.001). CAD was associated with lower odds of DM in whites but higher odds in Chinese, Malays and Indians (P = 0.001). AF was associated with lower adjusted odds of DM only in Chinese (P = 0.019). PVD was associated with higher odds of DM in whites and Malays (P = 0.044). CKD was associated with increased odds of DM in all ethnic groups except Malays (P = 0.100).
Clinical outcomes
Overall, DM was a significant predictor of 1-year mortality on univariable analysis but this association was attenuated after adjusting for confounders (HR 1.16, 95% CI 0.93-1.44; P = 0.18; Table 2 ). DM was not independently associated with increased risk of 1-year mortality for any individual ethnic group. Overall, DM was independently associated with HF hospitalizations at 1 year (HR 1.43, 95% CI 1.20-1.70).
For the entire cohort, DM was a significant predictor of the composite of 1-year mortality/HF hospitalization even after adjustment of confounders (HR 1.37, 95% CI 1.19-1.57; P < 0.001). This result was driven by the significant association between DM and 1-year mortality or HF hospitalization for blacks (HR 1.50, 95% CI 1.05-2.14), Chinese (HR 1.35, 95% CI 1.07-1.71), and Indians (HR 1.59, 95% CI 1.00-2.53). There was no significant interaction between ethnicity and DM for the outcome of 1-year mortality, 1-year HF hospitalization, or for the composite outcome (P = 0.26, P = 0.31, and P = 0.28, respectively).
Similarly, on multivariable analysis, DM was not a significant predictor of CV mortality (HR 1.16, 95% CI 0.90-1.51; P = 0.25; Table 2 ) but a significant predictor of the composite of CV mortality/HF hospitalization (HR 1.38, 95% CI 1.19-1.61; P < 0.001). There were no significant interactions between ethnicity and DM for both these outcomes (P = 0.30 and P = 0.14, respectively).
Discussion
The ethnic differences in patients with DM and HF have not been well-characterized previously. In this combined cohort of ethnically and geographically diverse patient populations with HFrEF, we found significant ethnic differences in the prevalence and . 
Prevalence of diabetes mellitus
The higher prevalence of DM in the HF patients of Asian ethnicities compared to whites is in line with prior studies which also show an increased prevalence of DM in Asian ethnicities in HF patients. 9, 16, 17 In our study, blacks also had a higher prevalence of DM than whites. Numerous studies have shown similar findings both in the general population as well as in HF patients. 1, 16, 18 This higher prevalence may be explained by a multitude of factors, including biological, environmental, and lifestyle.
19 -28 It is important to note that the rate of DM in this population of HF patients is higher than the rate of DM in the general population. According to the World Health Organization, as of 2014, the age-standardized prevalence of DM in adults in the countries included in this study is as follows: United States 8.4%, Canada 7.1%, France 6.3%, China 9.5%, India 9.5%, Indonesia 8.7%, Japan 7.5%, Korea 7.9%, Malaysia 11.1%, and Singapore 8.5%.
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Clinical correlates by ethnicity
Data on the ethnic differences among HF patients with DM are lacking. In our study, across ethnic groups, patients with DM had higher average BMIs than patients without DM; however, black and white patients with and without DM had markedly higher BMIs compared to DM and non-DM patients in the Asian ethnicities. In the general diabetic population, prior work has shown that Asian patients develop DM at a lower BMI than in other regions of the world. 30 Obesity is a major cause of DM in Western cohorts. However, insulin resistance and increased abdominal or visceral fat are seen in non-obese Asian adult populations, even from a young age. Indian men in the United States demonstrate insulin resistance even without increased intraperitoneal fat mass compared to the white men. 31 South Asian populations have been shown to have a low glucose disposal rate and adiponectin levels, but high leptin levels 31 ; with low adiponectin levels associated with low insulin sensitivity and high prevalence in Asians. 32 In HF patients, similar findings have been shown in a study comparing patients from Sweden and Singapore. 9 Despite the leaner phenotype of diabetics in Asians, we have shown that increasing BMI has been associated with higher odds of DM in all ethnicities. This is consistent with prior studies that have shown that with the development of obesity in Asians, metabolic abnormalities are further exaggerated.
All ethnicities were similar in that patients with DM had higher rates of CV co-morbidities compared to patients without DM. Hypertension was associated with DM for all ethnic groups. Black patients had the lowest rate of CKD, whereas Malay patients had the highest rate; however, CKD was not associated with DM in Malay patients, but was associated Figure 2 Significant clinical correlates of diabetes mellitus by ethnicity. BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; PVD, peripheral vascular disease; SD, standard deviation. Significant multivariable P-value for interaction for all. *Odds ratio 8.0 (out of range). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . with DM in all other ethnic groups. These different ethnic findings highlight the complexity of the role ethnicity plays in DM.
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In addition to ethnic differences in clinical characteristics, we also found differences in how DM affects quality of life in patients with HF. Japanese/Korean patients largely had the highest rating of health status, with little difference between those with and without DM. White patients also had relatively high scores for the domains in the KCCQ questionnaire, though those with DM had a higher burden of physical limitations than those without DM. However, among all ethnicities, DM negatively impacted the quality of life and health status for Indian patients more than for patients of other ethnic groups. These results highlight the impact of regional and ethnic differences in how patients internalize and experience illness. Ethnicity embodies not only genetic variation but also distinct differences in culture and lifestyle. These interesting findings form a firm foundation for future research.
Clinical outcomes
In our study, we found DM to be a significant predictor of the combined outcomes of mortality and HF hospitalizations independent of ethnicity; there was a trend towards increased mortality alone but this effect was attenuated after adjustment for confounders. These results are similar to data from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF), which found that DM was an independent predictor of rehospitalization but not of 90-day mortality, 8 as well as the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study which showed DM was a predictor of 1-year mortality on univariate analysis but not on multivariate analysis. 33 In contrast, a study from the European Society of Cardiology Heart Failure Long-Term Registry showed DM to be an independent predictor of 1-year mortality, though the . ethnic breakdown of patients included in this study differed from our present study. 34 Several other studies found that DM was a significant predictor of mortality over a longer period of time ranging from 2 to 8 years. 35 -37 In the first year, DM may have less of an impact on mortality in HF patients who are already at high risk of death, but over longer periods of time, DM may have a larger impact on mortality.
With respect to ethnicity, there was no significant interaction with DM for outcomes; however, DM appeared to be associated with increased risk of mortality or HF hospitalizations in certain ethnicities (black, Chinese, Indian) but not others. Data on the impact of ethnicity and DM on outcomes in HF patients are scarce. One study comparing Swedes and South-east Asians found that DM similarly resulted in the increased combined outcome of HF hospitalizations and mortality in both groups, although the impact was found to be greater in South-east Asians. The study analysed Chinese, Malays and Indians together as a group and did not investigate the impact of individual ethnicities. Studies have shown that significant ethnic differences exist between the various Asian ethnicities and Chinese, Malays and Indians may not be readily generalizable as one Asian cohort. Furthermore, the Asian data were derived from only one country and the Western data were represented by Sweden which may not necessarily be applicable to other Western populations (in our case, blacks and whites from the United States).
Taken together, these results suggest that DM in general is a detrimental disease that has a negative impact on outcomes in patients with HFrEF regardless of ethnicities, though some ethnicities are at higher risk of adverse outcomes. Unmeasurable factors like differences in culture, diet, lifestyle as well as disease screening and management practices may confound the results. Previously published data from the ASIAN-HF registry showed significant regional variations in co-morbidities within subjects from the same ethnic group, demonstrating that regional lifestyle factors may play a role in these associations.
Limitations
First, ethnicity was self-reported, so these results may not reflect biological or genetic differences between groups. Second, there may be inherent limitations in the combination of two diverse datasets, one from a clinical trial and one from a registry, though most of the merged variables are standard and have been well defined globally. We were, however, limited by the data collected in the original studies. We did not have information about specific diabetic medications or severity of DM, for example. In addition, we did not have information about other outcomes, such as hypoglycaemic events or non-cardiac causes of morbidity or mortality. Third, there may be selection biases from the different sites. However, protocol standardization and adherence across all sites were enforced via frequent audits. Fourth, as with all retrospective analyses, there are potential measured and unmeasured confounders which may have influenced the results. For example, socioeconomic status, lifestyle differences, health care accessibility, and differences in screening practices or DM control, were unable to be accounted for in this study. Moreover, differences in screening practices may have introduced selection bias for those with more severe DM. Careful adjustment for region/country was performed in all analyses to minimize potential geographic differences.
Conclusions
There is marked heterogeneity in the prevalence and risk of DM among patients with HF among different ethnic groups. Despite this, DM increases the combined risk of morbidity and mortality outcomes in HF patients, independent of ethnicity. Concerted efforts should be made to tackle this significant public health problem worldwide. Conflict of interest: none declared.
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